Ben J.L. Van den Branden

Showing 1-8 of 8 articles

Interventions for valvular disease

Impact of mitral valve treatment choice on mortality according to aetiology

Kortlandt F, Velu J, Schurer R, Van den Branden B, Bouma B, Kelder J, Eefting F, Swaans M, Rensing B, Baan Jr J, Van der Heyden J

April 16, 2019 | 10.4244/EIJ-D-18-00874

Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions

Teeuwen K, Van den Branden B, Koolen J, van der Schaaf R, Henriques J, Thijssen J, Kelder J, Vermeersch P, Rensing B, Suttorp MJ

March 20, 2015 | 10.4244/EIJY14M08_07

Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions

Van den Branden B, Teeuwen K, Koolen J, van der Schaaf R, Henriques J, Thijssen J, Kelder J, Vermeersch P, Rensing B, Suttorp MJ

November 29, 2013 | 10.4244/EIJV9I7A138

Late catch-up in lumen diameter at five-year angiography in MACE-free patients treated with sirolimus-eluting stents in the Primary Stenting of Totally Occluded Native Coronary Arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II)

Teeuwen K, Van den Branden B, Rahel B, Laarman G, Thijssen J, Kelder J, Slagboom T, ten Berg J, Suttorp MJ

June 28, 2013 | 10.4244/EIJV9I2A36

Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study)

Van den Branden B, Rahel B, Laarman G, Slagboom T, Kelder J, ten Berg J, Suttorp MJ

February 21, 2012 | 10.4244/EIJV7I10A190

The BioSTAR® device versus the CardioSEAL® device in patent foramen ovale closure: comparison of mid-term efficacy and safety

Van den Branden B, Luermans J, Post M, Plokker H, ten Berg J, Suttorp MJ

September 30, 2010

Re-examining minimal luminal diameter relocation and quantitative coronary angiography - intravascular ultrasound correlations in stented saphenous vein grafts: methodological insights from the randomised RRISC trial

Semeraro O, Agostoni P, Verheye S, van Langenhove G, Van den Heuvel P, Convens C, Van den Branden B, Bruining N, Vermeersch P

March 20, 2009

One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with <i>de novo</i> native coronary artery lesions: the SPIRIT II study

Ruygrok P, Desaga M, Van den Branden B, Rasmussen K, Suryapranata H, Dorange C, Veldhof S, Serruys P

November 20, 2007

1

Latest news

Infective Endocarditis & TAVI; Cerebral Protection Devices; IVUS Assessment in ViV-TAVI, Mini Focus on Antithrombotic Therapy …

February 19, 2021

Don’t Miss #EIJOnAir 2nd Edition!

Elective cardiac invasive procedures during the COVID-19 outbreak

MitraClip for a range of LV dysfunction and secondary MR

Stamatios Lerakis et al.

Thrombolysis in ST-elevation myocardial infarction is not dead

Petr Kala et al.

SCOPE 2, COACT 1 year, FORZA, COMPARE CRUSH

(Thanks to the support of Biotronik)

February 28, 2021

This Week's JAA's: Impact of crossing strategy on CTO recanalisation outcomes and more...

Guidance Papers

Guidelines, consensus & position papers

August 28, 2020

Valvular disease